8BAC
Crystal structure of human heparanase in complex with competitive inhibitor GD05
This is a non-PDB format compatible entry.
Summary for 8BAC
| Entry DOI | 10.2210/pdb8bac/pdb |
| Descriptor | Heparanase 50 kDa subunit, Heparanase 8 kDa subunit, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (6 entities in total) |
| Functional Keywords | inhibitor complex, hydrolase |
| Biological source | Homo sapiens (human) More |
| Total number of polymer chains | 2 |
| Total formula weight | 52672.48 |
| Authors | Armstrong, Z.,Davies, G.J. (deposition date: 2022-10-11, release date: 2023-03-01, Last modification date: 2024-10-16) |
| Primary citation | Doherty, G.G.,Ler, G.J.M.,Wimmer, N.,Bernhardt, P.V.,Ashmus, R.A.,Vocadlo, D.J.,Armstrong, Z.,Davies, G.J.,Maccarana, M.,Li, J.P.,Kayal, Y.,Ferro, V. Synthesis of Uronic Acid 1-Azasugars as Putative Inhibitors of alpha-Iduronidase, beta-Glucuronidase and Heparanase. Chembiochem, 24:e202200619-e202200619, 2023 Cited by PubMed Abstract: 1-Azasugar analogues of l-iduronic acid (l-IdoA) and d-glucuronic acid (d-GlcA) and their corresponding enantiomers have been synthesized as potential pharmacological chaperones for mucopolysaccharidosis I (MPS I), a lysosomal storage disease caused by mutations in the gene encoding α-iduronidase (IDUA). The compounds were efficiently synthesized in nine or ten steps from d- or l-arabinose, and the structures were confirmed by X-ray crystallographic analysis of key intermediates. All compounds were inactive against IDUA, although l-IdoA-configured 8 moderately inhibited β-glucuronidase (β-GLU). The d-GlcA-configured 9 was a potent inhibitor of β-GLU and a moderate inhibitor of the endo-β-glucuronidase heparanase. Co-crystallization of 9 with heparanase revealed that the endocyclic nitrogen of 9 forms close interactions with both the catalytic acid and catalytic nucleophile. PubMed: 36453606DOI: 10.1002/cbic.202200619 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.05 Å) |
Structure validation
Download full validation report






